Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008

Chicago, Illinois — July 30, 2008 — ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today presented data from the company’s novel compound, ANAVEX 1-41, targeting Alzheimer’s disease, at the International Conference on Alzheimer’s Disease (ICAD)…